Presented by John Cottone, Ph.D.

Ketamine-assisted psychotherapy (KAP) is one of several forms of psychedelic-assisted treatments gaining traction in recent years. Though ketamine initially gained FDA-approval in 1970 as a surgical anesthetic, its off-label use as a psychiatric drug increased significantly in the 1990s, with more recent research investigations validating its efficacy in this context. Today, different forms of ketamine are used legally for psychiatric purposes, however, the FDA has authorized only one form for psychiatric use (i.e., the S+ form: generic name Esketamine; trade name Spravato), and its approval in such contexts is limited. Ketamine’s unique psychotropic benefits – especially when administered during a psychotherapy session – as well as its risks and availability will be discussed.

Dr. John G. Cottone is a psychologist in private practice in Stony Brook, NY and a clinical assistant professor of psychology at the Renaissance School of Medicine at Stony Brook University. He is the author of numerous peer reviewed research papers on the neurological correlates of mental illness, psychotherapy outcome, and, most recently, on ketamine-assisted psychotherapy. He is also a regular contributor to Psychology Today and Choosing Therapy and has had psychology-related publications in the New York Times and the Washington Post.

Register for this workshop